P593. A patient's perspective on anaemia in inflammatory bowel disease
C. Hoffman1, S. Vel1, M. Greco2, S. Danese2, H. Szabo2, B. Wilson2, L. Avedano2, 1Vifor Pharma Ltd, Glattbrugg, Switzerland, 2EFCCA, Brussels, Belgium
Anemia is frequently seen in patients with inflammatory bowel disease (IBD), and needs appropriate treatment. An online questionnaire investigated patient perception of anemia: its symptoms, prevalence, treatment, and its impact on quality of life.
Patients with IBD, either Crohn's disease (CD) or ulcerative colitis (UC), were invited to participate in an online survey between June-Sept 2012 developed in collaboration with EFCCA in 6 languages. Respondents were mainly from Europe but also included North America and the Asia Pacific region.
A total of 631 subjects (68% female) completed the questionnaire. CD was the most common presentation (60% women; 66% men) followed by UC (37% women; 29% men). Of the respondents 63–68% had been previously diagnosed with anemia, and of those who knew the date of diagnosis (n = 343) 17% were diagnosed prior to an IBD diagnosis, 32% at the time, and 51% after (average time for anemia diagnosis was 6.7 years). When asked about anaemia in IBD, 43% considered it frequent (ie in 50–70% of cases) and most associated it with blood loss (45%), iron deficiency (31%), or inflammation (18%). The most common symptoms reported by anemia sufferers and those not diagnosed with anemia were fatigue/tiredness (86% vs. 76% respectively) and weakness (72% vs. 40% respectively). Fatigue was experienced nearly every day by 53% and 40%, respectively. 57% had been prescribed treatment for anemia (26% were receiving prescription medication at the time of survey and 9% were taking non-prescription treatments). In subjects on anemia treatments, 42% took oral prescription iron, 27% intravenous (IV) iron, 19% non-prescription iron supplements, and 10% prescription liquid/syrup iron. The majority of subjects taking liquid/syrup iron (77%), oral iron (74%) and iron supplements (68%) were dissatisfied with their treatment (ie 1–7 point scale where 1 was very unsatisfied and 7 was very satisfied) primarily due to poor tolerability. In contrast, 72% prescribed IV iron were satisfied with the treatment. In those diagnosed with anemia, fatigue had a major negative impact on daily life including physical activities, productivity, and home life (76%, 63% and 60% respectively).
Anemia occurs in many IBD subjects and most are aware of the main signs and symptoms. The most commonly prescribed treatment is oral iron (42%) but many patients are dissatisfied due to tolerability issues. Of those prescribed IV iron (27%) the majority are satisfied with this treatment.